“Bringing Dr. Fenge into the management team strengthens our ability to accelerate the commercialization and the strategic partnerships with customers and turnkey solution providers in bioprocessing,” says Laura Chirica, CEO of Cellevate. “Her deep expertise in upstream bioprocessing, combined with strategic leadership, will be invaluable as we continue to commercialize and implement Cellevat3d nanofiber cell culture solutions in new therapeutic large-scale applications, develop new product families and position our company as a proven provider in this industry.”

Christel Fenge

Dr. Christel Fenge, who has served as a Strategic Advisor to Cellevate since June 2024, brings over 30 years of experience in leadership roles within the bioprocessing and biopharmaceutical industries, describes the company. Previous positions include VP, R&D Bioprocess at Cytiva and VP, Marketing & Product Management at Sartorius, overseeing upstream and downstream development and commercialization. This expertise will be instrumental in scaling up Cellevate’s groundbreaking nanofiber-based cell culture products.

“The company’s commercially available nanofiber-based cell culture systems have already shown great potential in biomanufacturing, and I look forward to supporting the team as we now have moved into commercialization and scale-up,” says Christel Fenge.